Analysts’ Opinions Are Mixed on These Healthcare Stocks: Enlivex (ENLV), MacroGenics (MGNX) and Immuneering (IMRX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Enlivex (ENLV – Research Report), MacroGenics (MGNX – Research Report) and Immuneering (IMRX – Research Report).

Enlivex (ENLV)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Enlivex today and set a price target of $7.00. The company’s shares closed last Thursday at $1.83.

According to TipRanks.com, Selvaraju is a 5-star analyst with an average return of 11.3% and a 38.8% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding, Reviva Pharmaceuticals Holdings, and MoonLake Immunotherapeutics.

Currently, the analyst consensus on Enlivex is a Moderate Buy with an average price target of $7.00.

See Insiders’ Hot Stocks on TipRanks >>

MacroGenics (MGNX)

H.C. Wainwright analyst Robert Burns reiterated a Hold rating on MacroGenics today and set a price target of $16.00. The company’s shares closed last Thursday at $18.51.

According to TipRanks.com, Burns ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -23.4% and a 23.0% success rate. Burns covers the Healthcare sector, focusing on stocks such as Black Diamond Therapeutics, Springworks Therapeutics, and Calidi Biotherapeutics.

MacroGenics has an analyst consensus of Strong Buy, with a price target consensus of $23.57, which is a 27.9% upside from current levels. In a report issued on April 4, TD Cowen also maintained a Hold rating on the stock.

Immuneering (IMRX)

Needham analyst Ami Fadia maintained a Buy rating on Immuneering today and set a price target of $15.00. The company’s shares closed last Thursday at $2.08, close to its 52-week low of $1.90.

According to TipRanks.com, Fadia is a 3-star analyst with an average return of 2.7% and a 42.9% success rate. Fadia covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Day One Biopharmaceuticals, and Intra-Cellular Therapies.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Immuneering with a $11.83 average price target, implying a 477.1% upside from current levels. In a report issued on April 10, Mizuho Securities also maintained a Buy rating on the stock with a $8.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ENLV:

• Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis
• Enlivex’s Allocetra™ Shows Promise in Sepsis Trial
• Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
• Enlivex Therapeutics’ Stable Financial Outlook